236 related articles for article (PubMed ID: 28626036)
1. Treating ER+ Breast Cancer with CDK4/6 Inhibitors.
Cancer Discov; 2017 Aug; 7(8):OF4. PubMed ID: 28626036
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
3. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
4. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
5. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
6. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
Sharifi MN; Anandan A; Grogan P; O'Regan RM
Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
[TBL] [Abstract][Full Text] [Related]
7. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
[TBL] [Abstract][Full Text] [Related]
10. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.
Scheidemann ER; Shajahan-Haq AN
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830174
[TBL] [Abstract][Full Text] [Related]
11. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
12. Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
Wander SA; Bardia A
Clin Cancer Res; 2024 May; 30(10):2008-2010. PubMed ID: 38319645
[TBL] [Abstract][Full Text] [Related]
13. Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors.
McCartney A; Malorni L
Br J Cancer; 2020 Jul; 123(2):176-177. PubMed ID: 32382111
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
15. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
16. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer.
Portman N; Alexandrou S; Carson E; Wang S; Lim E; Caldon CE
Endocr Relat Cancer; 2019 Jan; 26(1):R15-R30. PubMed ID: 30389903
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
18. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers.
Finn RS; Aleshin A; Slamon DJ
Breast Cancer Res; 2016 Feb; 18(1):17. PubMed ID: 26857361
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
20. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions.
Roncato R; Angelini J; Pani A; Cecchin E; Sartore-Bianchi A; Siena S; De Mattia E; Scaglione F; Toffoli G
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32883002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
